Impact of The Research Programs We Support
The Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai
While there are a growing number of new treatments for Inflammatory Bowel Disease (IBD), we are still trying to identify how to select the best treatments for individual patients. Recently, genetic variants were discovered that affect how patients respond to two of the most common medications in IBD, which are anti-TNF alpha therapy (e.g. infliximab and adalimumab) and thiopurines (e.g. 6-MP and azathioprine). The genetic variants can also predict which side effects a patient may experience from a particular drug. However the only variant being used by doctors today is the one which determines how patients respond to the class of drugs known as thiopurines. Click here to continue reading.
The Pediatric Inflammatory Bowel Disease (IBD) Program, Dr. Shervin Rabizadeh, MD, MBA
Research Projects Supported by Connecting to Cure Crohn’s and Colitis:
The Pediatric Inflammatory Bowel Disease (IBD) Program at Cedars-Sinai Medical Center continues to thrive as the premier center in both clinical work and research caring for children with Crohn’s disease and ulcerative colitis—known collectively as IBD.
The previous and ongoing contributions of Connecting to Cure Crohn’s and Colitis have been critical to the mission of the Cedars-Sinai Pediatric IBD Program in advancing research objectives. The program has a multitude of ongoing research projects and the ones listed below have been most directly impacted. Click here to continue reading.
The Inflammatory Bowel Disease (IBD) Program at Mayo Clinic, Dr. William Faubian, JR, MD
We are supporting research of Dr. William Faubion and Dr. Laura Raffals called “Defining IBD Disease Phenotypes”. The goal of their work is to develop a complete multi-omics data resource for Inflammatory Bowel Disease (IBD). Through integration of multi-dimensional molecular phenotyping of patients with IBD, we will resolve underlying pathophysiologic mechanisms enabling precision individualized therapy. Their work involves a data generation and analysis strategy combining genome-wide sequencing technologies, microbial metabolomics, and a functional cellular immune response platform on stool and cells isolated from patients. They hypothesize that multi-parameter data integration of the same exquisitely phenotyped patient will reveal distinct immunologic and microbial-induced pathways/molecular signatures determining IBD severity.
Their collection and integration of datasets will serve as the basis for hypothesis-generating and discovery-based science aimed at identifying molecular predictors of IBD. Integrated, multi-dimensional molecular barcodes of disease will foster breakthroughs in therapeutic stratification to guide improved, predictable, more cost-effective outcomes. Data generated in this grant will serve as preliminary data for subsequent funded larger trials.